Results 11 to 20 of about 14,564 (189)

Aflibercept

Reactions Weekly, 2022
Aflibercept is a medication used to treat and manage neovascular age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, macular edema associated with retinal vein occlusion, and diabetic retinopathy.
Sorhaitz, Winston, Stringham, Jack, Adams, Bryan S.   +2 more
core   +6 more sources

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.

PLoS ONE, 2022
PurposeTo assess the interaction between ranibizumab, aflibercept, and mouse vascular endothelial growth factor (VEGF), both in vivo and in vitro.MethodsIn vivo, the effect of intravitreal injection of ranibizumab and aflibercept on oxygen induced ...
Yusuke Ichiyama, Riko Matsumoto, Shumpei Obata, Osamu Sawada, Yoshitsugu Saishin, Masashi Kakinoki, Tomoko Sawada, Masahito Ohji   +7 more
doaj   +3 more sources

Proteome Analysis of Aflibercept Intervention in Experimental Central Retinal Vein Occlusion

Molecules, 2022
Aflibercept is a frequently used inhibitor of vascular endothelial growth factor (VEGF) in the treatment of macular edema following central retinal vein occlusion (CRVO).
Lasse Jørgensen Cehofski, Anders Kruse, Benn Falch Sejergaard   +2 more
exaly   +3 more sources

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab

International Medical Case Reports Journal, 2018
Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Athina Pallikari, Constantine D Georgakopoulos Department of Ophthalmology, University of Patras, Patras, Greece Purpose: To report the 12-month outcomes of a patient switching from intravitreal ...
Makri OE, Tsapardoni FN, Plotas P, Pallikari A, Georgakopoulos CD   +4 more
doaj   +1 more source

Current role of aflibercept in retinopathy of prematurity – A review [PDF]

Indian Journal of Ophthalmology
The introduction of intravitreal anti-vascular endothelial growth factor (VEGF) therapy has transformed the management of severe retinopathy of prematurity (ROP) in the zone I/zone II posterior region and aggressive ROP by enabling rapid disease ...
Devesh Kumawat, Nawazish Shaikh, Parijat Chandra   +2 more
doaj   +2 more sources

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources

The clinical utility of aflibercept for diabetic macular edema

Diabetes, Metabolic Syndrome and Obesity, 2015
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular
Stewart MW
doaj   +1 more source

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept

Indian Journal of Ophthalmology
Purpose: To investigate the 12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration (nAMD) in eyes previously treated with aflibercept.
Wajiha J Kheir, Mahdi Hassoun, Rola N Hamam, Ziad Fayez Bashshur   +3 more
doaj   +2 more sources

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration

Clinical Ophthalmology, 2018
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3 1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of
Taipale C, Laine I, Tuuminen R
doaj   +1 more source

Aflibercept [PDF]

Clinical Cancer Research, 2013
Abstract Aflibercept, an intravenously administered anti-VEGF and antiplacental growth factor (PlGF) agent, has recently been approved by the U.S. Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously ...
Kristen K, Ciombor, Jordan, Berlin, Emily, Chan   +2 more
  +6 more sources